Short answer
It is not FDA-approved for any use, and as of October 2026 it is not on the list of substances US pharmacies may compound. An FDA advisory committee voted in July 2026 to recommend adding it, but that vote is non-binding and the FDA has not finished the rulemaking. It is banned in sport by WADA.
Where the FDA stands today
BPC-157 is not part of any FDA-approved drug and has no official drug standard, according to the FDA's own briefing document. In 2023 the FDA placed it in its Category 2 list of compounding substances with significant safety risks. In April 2026 it came off that list, but only because the nominations were withdrawn, not because the FDA cleared it.
Coming off Category 2 is not the same as being allowed. For a substance like BPC-157, a pharmacy compounding under section 503A generally needs it to be on the FDA's 503A bulks list, and it is not on that list.
What the July 2026 vote did and did not do
On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee discussed BPC-157 for one proposed use, ulcerative colitis. FDA staff had recommended against adding it, citing poor chemical characterization, too little safety and immune-reaction data, and not enough evidence it works. The committee voted narrowly in favor, according to reports from the meeting.
Advisory votes are recommendations. The FDA must still propose and finalize a rule. As of early October 2026 we found no proposed rule in the Federal Register.
What the FDA says about safety
The FDA's current entry says compounded BPC-157 may pose a risk of immune reactions for certain routes, may have impurity problems, and that the agency lacks enough information to know whether it would cause harm in people.
Athletes should know it is on the World Anti-Doping Agency's prohibited list as a non-approved substance, banned at all times. Educational content, not legal or medical advice.
Related questions
Did the FDA approve BPC-157 in 2026?
No. An advisory committee recommended adding it to the compounding list, which is different from approval. Neither step makes it an FDA-approved drug.
Is BPC-157 allowed in dietary supplements?
The FDA's briefing document notes it is marketed as a supplement ingredient. In 2023 the FDA called BPC-157 an unapproved new drug in a warning letter to a seller. Check the FDA's warning letters before trusting any label.
Read next
Sources
- FDA: bulk drug substances that may present significant safety risks (BPC-157 entry, current as of 22 Apr 2026)
- FDA Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026
- FDA briefing document on BPC-157 for the July 2026 committee meeting
- FDA warning letter to Warrior Labz SARMS, 12 Jun 2023 (BPC-157 as an unapproved new drug)
- WADA Prohibited List, S0 Non-Approved Substances
Published 2026-10-03 · Last checked 2026-10-03
Educational content, not medical advice. Made for the United States.